Older adults who received the high-dose influenza vaccine had roughly 55 percent lower odds of developing Alzheimer's dementia compared with those who received the standard-dose shot, according to a study of about 200,000 adults aged 65 and older published in the journal Neurology.
The research, led by Dr. Paul E. Schulz of UTHealth Houston with corresponding author Dr. Avram Samuel Bukhbinder of Massachusetts General Hospital and Harvard, builds on the team's 2022 finding that standard-dose flu vaccination was already associated with about a 40 percent lower Alzheimer's risk. The high-dose vaccine, which contains four times the antigen of the standard shot and is preferentially recommended by the CDC for seniors, appeared to confer additional protection beyond that baseline effect. The protective association appeared stronger in women, though the study did not report separate numeric estimates for that subgroup.
Why the finding matters — and its limits
More than 7 million Americans 65 and older had Alzheimer's disease as of 2025, roughly one in nine people in that age group, with projections suggesting the number could more than double by 2050. A vaccine-linked reduction in risk, if confirmed, would represent an unusually simple and widely available intervention.
But the study is observational, not a randomized trial, and dose selection was partly driven by vaccine supply and clinical judgment rather than random assignment — meaning healthier patients may have been more likely to receive the high-dose shot for reasons unrelated to any true biological effect, a form of confounding the press materials did not directly address. The researchers have not identified a specific biological mechanism linking flu vaccination to reduced Alzheimer's risk, and the study's funding sources were not disclosed in available coverage. "I was stunned that, as a physician, I didn't know a higher dose was offered," Schulz said, a comment that speaks to awareness gaps among clinicians more than to causation.
What would strengthen the case
Researchers say a randomized controlled trial comparing standard- and high-dose vaccination with dementia outcomes as a pre-specified endpoint would be needed to establish whether the vaccine itself drives the lower risk, or whether the association instead reflects differences between the kinds of patients who receive each dose. Until such a trial exists, the finding should be treated as a strong statistical association rather than proof of a protective effect.
